Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Account Payables (2017 - 2025)

Historic Change in Account Payables for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $3.0 million.

  • Dianthus Therapeutics' Change in Account Payables fell 4684.13% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 853.07%. This contributed to the annual value of $8.2 million for FY2024, which is 113918.31% up from last year.
  • According to the latest figures from Q3 2025, Dianthus Therapeutics' Change in Account Payables is $3.0 million, which was down 4684.13% from $3.1 million recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Change in Account Payables peaked at $5.7 million during Q3 2024, and registered a low of -$4.7 million during Q1 2023.
  • For the 4-year period, Dianthus Therapeutics' Change in Account Payables averaged around $842933.3, with its median value being $1.4 million (2022).
  • Its Change in Account Payables has fluctuated over the past 5 years, first tumbled by 43826.9% in 2023, then soared by 63104.79% in 2024.
  • Dianthus Therapeutics' Change in Account Payables (Quarter) stood at -$339000.0 in 2022, then surged by 572.86% to $1.6 million in 2023, then skyrocketed by 42.23% to $2.3 million in 2024, then skyrocketed by 31.75% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $3.1 million for Q2 2025, and -$1.5 million during Q1 2025.